ANIP Stock Overview
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ANI Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.72 |
| 52 Week High | US$70.00 |
| 52 Week Low | US$52.50 |
| Beta | 0.49 |
| 1 Month Change | 9.97% |
| 3 Month Change | 26.88% |
| 1 Year Change | 3.65% |
| 3 Year Change | 120.26% |
| 5 Year Change | 57.47% |
| Change since IPO | 990.79% |
Recent News & Updates
Recent updates
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth
Mar 28
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Feb 25ANI Pharmaceuticals: More Than Just A Generics Company
Feb 11ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares
Dec 18Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly
Nov 09ANI Pharmaceuticals Is Acting Like It Is Being Acquired
Nov 02ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market
Oct 11
Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector
Sep 15 Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues
Sep 10ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Aug 14Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?
Aug 08ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
Aug 02Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price
Jun 10ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked
Jun 10These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well
Feb 17Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings
Nov 15Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Sep 22Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?
Feb 22Shareholder Returns
| ANIP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | 1.4% | 6.8% |
| 1Y | 3.7% | -7.0% | 5.9% |
Return vs Industry: ANIP exceeded the US Pharmaceuticals industry which returned -8.6% over the past year.
Return vs Market: ANIP underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| ANIP volatility | |
|---|---|
| ANIP Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ANIP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANIP's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 897 | Nikhil Lalwani | www.anipharmaceuticals.com |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.
ANI Pharmaceuticals, Inc. Fundamentals Summary
| ANIP fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$20.15m |
| Revenue (TTM) | US$614.38m |
2.3x
P/S Ratio-69.3x
P/E RatioIs ANIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANIP income statement (TTM) | |
|---|---|
| Revenue | US$614.38m |
| Cost of Revenue | US$250.21m |
| Gross Profit | US$364.17m |
| Other Expenses | US$384.31m |
| Earnings | -US$20.15m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 09, 2025
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 59.27% |
| Net Profit Margin | -3.28% |
| Debt/Equity Ratio | 145.6% |
How did ANIP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 07:32 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ANI Pharmaceuticals, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Timothy Chiang | Capital One Securities, Inc. |
| Vamil Divan | Guggenheim Securities, LLC |